Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Assets: 2010-2025

Historic Assets for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $904.9 million.

  • Iovance Biotherapeutics' Assets was N/A to $904.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $904.9 million, marking a year-over-year change of. This contributed to the annual value of $910.4 million for FY2024, which is 16.67% up from last year.
  • Iovance Biotherapeutics' Assets amounted to $904.9 million in Q3 2025, which was down 0.27% from $907.4 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Assets registered a high of $966.7 million during Q1 2025, and its lowest value of $757.3 million during Q2 2023.
  • Its 3-year average for Assets is $863.8 million, with a median of $869.8 million in 2024.
  • Data for Iovance Biotherapeutics' Assets shows a peak YoY grew of 16.67% (in 2024) over the last 5 years.
  • Iovance Biotherapeutics' Assets (Quarterly) stood at $780.4 million in 2023, then climbed by 16.67% to $910.4 million in 2024, then grew by 11.14% to $904.9 million in 2025.
  • Its last three reported values are $904.9 million in Q3 2025, $907.4 million for Q2 2025, and $966.7 million during Q1 2025.